Manufacturing

JLL, a real estate and investment management firm, recently released a new report on three trends shaping labs for the future of life sciences R&D.

Catalent completes $4.6 million expansion at Singapore clinical supply facility and marks 20 years in the region.

Modeling at various stages of the data analytics continuum aids scale comparison of a bioreactor.

Lower costs, fewer opportunities for temperature excursions, and a smaller carbon footprint are making ocean transport more attractive for pharmaceuticals. Poseidon, a new collaborative pharma initiative, seeks to leverage benefits.

Alan Kennedy, executive director of TEAM UP, shared perspectives on Poseidon and ocean transport.

Spectroscopic tools present an alternative method for reliable at-line process monitoring and control.

Biologic new molecular entities (NMEs) accounted for 26% of total NME approvals in 2017.

The contract development and manufacturing organization has entered it first manufacturing contract worth $148 million for its recently completed Plant 3 facility.

The company is voluntarily recalling three lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL Vial and one lot of Labetalol Hydrochloride Injection, USP, Novaplus because of the potential of cracked glass at the rim of the vials.

The company aims to add the additional analytical services in the European Union throughout 2018.

The new training center, the Jefferson Institute for Bioprocessing, will prepare engineering students and industry professionals for the field of biologics manufacturing.

Avid Bioservices will provide commercial manufacture of an enzyme replacement therapy by Roivant Sciences' Enzyvant subsidiary.

The agreement follows the recent opening of WuXi STA's oligonucleotide R&D labs in China and the US.

The companies have partnered to develop and commercialize vectorized antibodies against tau for Alzheimer's and other neurodegenerative diseases.

The study suggests that circumventing evolution in cell factories can enable the commercialization of new biobased chemicals to large-scale.

The company has expanded its single-use manufacturing capabilities at its facility in Fermoy, Ireland.

Fluarix Tetra has been approved for use in children aged six months and above.

Ompi EZ-fill vials and Daikyo Seiko PLASCAP press-fit closures are a confirmed product set for use with Vanrx Pharmasystems' Aseptic Filling Workcells.

Ferring Pharmaceuticals will expand its biologics capabilities at its headquarters and manufacturing site in Saint-Prex, Switzerland.

Unlike current approaches where bioconjugation is typically done following the manufacture of the monoclonal antibody and the cytotoxic drug, the new method begins with the antibody supernatants and eliminates the need for extensive chromatographic purification.

Honeywell offers an augmented/virtual reality approach to train the industrial workforce.

The companies have been awarded a collaborative grant of £1.9 million (US$2.6 million) from Innovate UK.

Amgen plans to invest approximately $300 million in a new biomanufacturing plant in the United States.

Shire will receive exclusive license to develop and commercialize AB Biosciences' pan receptor interacting molecule program for autoimmune and inflammatory diseases.

A collaboration between The Centre for Process Innovation and The Roslin Institute aims to develop commercially viable and scalable methods of producing biologics using transgenic animals.